Want to see JP:4575 full AI Analyst Report?

CanBas Co., Ltd. (4575) Price & Analysis

0 Followers

4575 Stock Chart & Stats

¥787.00

-¥23.00(-2.48%)

At close: Jan 08 4:00 PM EST

¥787.00

-¥23.00(-2.48%)

Day’s Range― - ―

52-Week Range¥506.00 - ¥1,558.00

Previous CloseN/A

Volume347.00K

Average Volume (3M)268.48K

Market Cap

¥14.08B

Enterprise Value¥9.66B

Total Cash (Recent Filing)¥1.77B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-61.18

Shares Outstanding19,713,655

10 Day Avg. Volume208,910

30 Day Avg. Volume268,476

Financial Highlights & Ratios

PEG Ratio1.96

Price to Book (P/B)7.69

Price to Sales (P/S)0.00

P/FCF Ratio-29.34

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

De-levered Balance SheetA zero-debt position and materially higher equity reduce near-term solvency risk and interest burdens, giving management more flexibility to fund R&D or negotiate partnerships without immediate refinancing. This durable capital structure supports survival through multi-year development timelines.

Licensing / Collaboration Revenue ModelAn IP/licensing and collaboration-driven model enables non-dilutive milestone and royalty revenue if assets advance, and lets the company leverage partners' commercial capabilities. Structurally, this reduces the need for large commercial build-outs and aligns incentives with partners over multi-year programs.

Focused Antibody Therapeutics R&DA concentrated focus on antibody therapeutics and drug discovery targets high unmet medical need and premium valuation if clinical progress occurs. Sustained R&D specialization builds technical know-how and IP that can generate durable, high-value partnership opportunities over years.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow forces ongoing external financing or dilutive transactions, which can compress shareholder value and constrain long-term program funding. Even with improvement, continued burn creates dependency on capital markets or partners over multi-year development cycles.

Minimal Current RevenueWith revenue near zero, the company lacks a recurring income base to fund operations or validate commercial traction. This raises execution risk because milestone or collaboration receipts are uncertain in timing and amount, worsening visibility into sustainable funding and growth.

Negative Returns On EquityA roughly -39% ROE signals that shareholder capital is being eroded rather than deployed profitably. Over the medium term, persistently negative returns imply weak capital efficiency and raise questions about management's ability to convert R&D investment into commercially valuable assets without further financing.

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?

CanBas Co., Ltd. lowest stock price was ¥506.00 and its highest was ¥1558.00 in the past 12 months.

What is CanBas Co., Ltd.’s market cap?

CanBas Co., Ltd.’s market cap is ¥14.08B.

When is CanBas Co., Ltd.’s upcoming earnings report date?

CanBas Co., Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 18 days.

How were CanBas Co., Ltd.’s earnings last quarter?

CanBas Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥15.48 earnings per share for the quarter, missing the consensus estimate of N/A by -¥15.48.

Is CanBas Co., Ltd. overvalued?

According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CanBas Co., Ltd. pay dividends?

CanBas Co., Ltd. does not currently pay dividends.

What is CanBas Co., Ltd.’s EPS estimate?

CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CanBas Co., Ltd. have?

CanBas Co., Ltd. has 19,713,655 shares outstanding.

What happened to CanBas Co., Ltd.’s price movement after its last earnings report?

CanBas Co., Ltd. reported an EPS of -¥15.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of CanBas Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4575

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CanBas Co., Ltd.

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.